Data from the nuMoM2b study suggests greater adherence to a Mediterranean diet was associated with reductions of 37%, 28%, and 21% in odds of gestational diabetes, preeclampsia, and any adverse pregnancy outcome, respectively, among a cohort of more than 7000 nulliparous women.
An analysis of data from the Japanese Collaborative Cohort Study for Evaluation of Cancer Risk suggests those with grade 2-3 hypertension could be increasing their risk of cardiovascular death by consuming 2 or more cups of coffee per day.
Data from the BCQR-T1D study, which was funded by the National Institutes of Health, suggest use of the dopamine receptor agonist bromocriptine was associated with improved blood pressure and arterial stiffness after 4 weeks of treatment in youth with type 1 diabetes.
An analysis of data from deliveries occurring at a large, urban medical center in Boston from 2016-2018 suggests more than 10% of women with no history of hypertension developed hypertension within a year after delivery.
Phase 2 data from the BrigHTN trial suggest use of 2 mg baxdrostat was associated with significantly and substantially reduced systolic and diastolic blood pressure in patients with treatment-resistant hypertension. In a Q&A, trial investigator Deepak Bhatt, MD, MPH, provides further insight.
A pooled analysis of data from the RADIANCE-HTN TRIO, RADIANCE-HTN SOLO, and RADIANCE II trials provide a comprehensive overview of the potential reductions in blood pressure possible with renal denervation.
An analysis comparing prepandemic blood pressure management against blood pressure management during the first months of the COVID-19 pandemic details rising blood pressure and declining blood pressure control coinciding with the implementation of lockdown and stay-at-home orders.
A trial of 110 women suggests use of nifedipine extended-release leading up to delivery could reduce risk of severe hypertension events among pregnant women with preeclampsia without increasing risk of adverse neonatal outcomes.